| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARRDC3 |
| Uniprot No | Q96B67 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-414aa |
| 氨基酸序列 | MVLGKVKSLT ISFDCLNDSN VPVYSSGDTV SGRVNLEVTG EIRVKSLKIH ARGHAKVRWT ESRNAGSNTA YTQNYTEEVE YFNHKDILIG HERDDDNSEE GFHTIHSGRH EYAFSFELPQ TPLATSFEGR HGSVRYWVKA ELHRPWLLPV KLKKEFTVFE HIDINTPSLL SPQAGTKEKT LCCWFCTSGP ISLSAKIERK GYTPGESIQI FAEIENCSSR MVVPKAAIYQ TQAFYAKGKM KEVKQLVANL RGESLSSGKT ETWNGKLLKI PPVSPSILDC SIIRVEYSLM VYVDIPGAMD LFLNLPLVIG TIPLHPFGSR TSSVSSQCSM NMNWLSLSLP ERPEAPPSYA EVVTEEQRRN NLAPVSACDD FERALQGPLF AYIQEFRFLP PPLYSEIDPN PDQSADDRPS CPSR |
| 分子量 | 46 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"ARRDC3 suppresses breast cancer progression by negatively regulating integrin β4"**
- **作者**: Draheim KM, et al.
- **摘要**: 该研究发现ARRDC3通过与整合素β4互作抑制乳腺癌细胞迁移及转移，揭示了其作为肿瘤抑制因子的潜在作用。
2. **"The arrestin domain-containing protein 3 (ARRDC3) regulates adipocyte differentiation and glucose homeostasis"**
- **作者**: Patwari P, et al.
- **摘要**: 研究显示ARRDC3通过调控脂肪细胞分化及胰岛素信号通路影响糖代谢，可能与肥胖及糖尿病相关。
3. **"ARRDC3 modulates the oncogenic potential of HER2/neu by promoting receptor internalization and degradation"**
- **作者**: Lehman-McKeeman LD, et al.
- **摘要**: 发现ARRDC3通过促进HER2/neu受体的内吞和泛素化降解，抑制其致癌活性，为靶向治疗提供新思路。
4. **"ARRDC3 interacts with E3 ubiquitin ligases to regulate Notch signaling during development"**
- **作者**: Rauch JN, et al.
- **摘要**: 揭示ARRDC3作为E3泛素连接酶适配器调控Notch通路活性，影响发育过程中的细胞命运决定。
(注：以上文献信息为示例，实际引用需核实具体论文及发表细节。)
ARRDC3 (Arrestin Domain-Containing Protein 3) is a member of the α-arrestin family, a subgroup of arrestin-related proteins involved in regulating endocytic trafficking, signaling, and ubiquitination-mediated degradation of membrane receptors. Unlike β-arrestins, which primarily modulate G protein-coupled receptor (GPCR) desensitization, α-arrestins like ARRDC3 interact with E3 ubiquitin ligases (e.g., NEDD4. WWP2) through conserved PPxY motifs, facilitating substrate ubiquitination and lysosomal or proteasomal degradation. ARRDC3 contains two N-terminal arrestin domains and C-terminal motifs critical for mediating protein-protein interactions.
Functionally, ARRDC3 regulates diverse cellular processes, including metabolic homeostasis, cell migration, and tumor suppression. It modulates insulin signaling and adipocyte metabolism via its role in degrading β2-adrenergic receptors (β2-ARs) and integrins, impacting obesity and diabetes pathways. In cancer, ARRDC3 acts as a tumor suppressor by promoting oncoprotein degradation (e.g., NOTCH1) or inhibiting metastasis-related pathways. It is epigenetically silenced in certain cancers, correlating with poor prognosis. ARRDC3 also participates in extracellular vesicle (EV) formation through its interaction with syndecans and ALIX, influencing intercellular communication.
Studies highlight its tissue-specific roles and crosstalk with hypoxia, inflammation, and autophagy. Despite progress, its precise mechanisms and therapeutic potential remain under exploration.
×
